Use of rituximab in resistant thrombocytopenic purpura
Main Article Content
Keywords
Rituximab, Blood platelets, Platelet count, Hemorrhagic disorders, Purpura, thrombocytopenic
Abstract
Background: immune thrombocytopenic purpura is characterized by bleeding disorders associated with decreased platelet count secondary to antiplatelet autoantibodies. The aim of this study was to evaluate the utility of rituximab in the management of refractory immune thrombocytopenic purpura.
Clinical cases: four women with immune thrombocytopenic purpura unresponsiveness to standard therapy were evaluated in relation to clinical response and total platelets counts at different time intervals after rituximab administration. All four patients developed petechiae; two of them associated with ecchymosis, one with hematemesis and one more with transvaginal bleeding. The mean baseline platelet count was 5350/µL; in the 60th day after the first dose of rituximab the average was 175 250/µL. Complete remission was considered in three patients.
Conclusions: rituximab is a therapeutic option for refractory inmune thrombocytopenic purpura. Nevertheless, more studies are needed to evaluate its efficacy and safety.
References
Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002:346(13):995-1008.
George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, et al. Idiopathic thrombocytopenic purpura. Blood 1996:88(1):3-40.
Cines D, Bussel J. How I treat idiopathic thrombocytopenic purpura (ITP). Blood 2005;106(7): 2244-2251. Disponible en http://bloodjournal. hematologylibrary.org/content/106/7/2244. long
Godeau B, Provan D, Bussel J. Immune thrombocytopenic purpura in adults. Curr Opin Hematol 2007;14(5):535-556.
Godeau B, Chevret S, Varet B, Lefrère F, Zini JM, Bassom-pierre F, et al. French ATIP Study Group. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. Lancet 2002;359(9300):23-29.
Scaradavou A, Woo B, Woloski BM, Cunningham-Rundles S, Ettinger LJ, Aledort LM, et al. Intravenous anti-D treatment of thrombocytopenic purpura: experience in 272 patients. Blood 1997;89(8):2689-2700. Disponible en http://bloodjournal.hematologylibrary.org/content/89/8/2689. long
Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004;104(9):2623-2634. Disponible en http://bloodjournal.hematologylibrary.org/content/104/9/2623.long
Vesely SK, Perdue JJ, Rizvi MA, Terrell DR, George JN. Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: a systematic review. Ann Intern Med 2004;140(2):112-120.
George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88 (1):3-40. Disponible en http://bloodjournal. hematologylibrary.org/content/88/1/3.long
British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003 120(4):574-596.
Rodeghiero F, Ruggieri M. Is splenectomy still the gold standard for the treatment of chronic ITP? Am J Hematol 2008;83(2):91.
Dolan JP, Sheppard BC, DeLoughery TG. Splenectomy for immune thrombocytopenic purpura: surgery for the 21st century. Am J Hematol 2008;83(2):93-96.
Johnson AE, Gordon C, Palmer RG, Bacon PA. The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthritis Rheum 1995;38(4):551–558.
Cines DB, McMillan R. Management of adult idiopathic thrombocytopenic purpura. Annu Rev Med 2005;56:425-442.
Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006;6(5 Pt 1):859-866.
El-Habbash MM, Alwindi AM. Progress in immunotherapy rituximab. Saudi Med J 2007;28(11):1635-1644.16.
Bello C, Sotomayor EM. Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematology Am Soc Hematol Educ Program 2007:233-242.
Cooper N, Bussel, J. The pathogenesis of immune throm-bocytopaenic purpura. Br J Haematol 2006;133(4):364-374.
Sukati H, Watson HG, Urbaniak SJ, Barker RN. Mapping helper T-cell epitopes on platelet membrane glycoprotein IIIa in chronic autoimmune thrombocytopenic purpura. Blood 2007;109(10):4528-4538. Disponible en http://bloodjournal. hematologylibrary.org/content/109/10/4528. full.pdf
Semple, JW. T cell and cytokine abnormalities in patients with autoimmune thrombocytopenic purpura. Transfus Apher Sci 2003;28(3):237-242.
Yu J, Heck S, Patel V, Levan J, Yu Y, Bussel JB, Yazdan-bakhsh K. Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood 2008;112(4):1325-1328. Disponible en http:// www. ncbi.nlm.nih.gov/pmc/articles/PMC2515134/?tool= pubmed
García-Chávez J, Majluf-Cruz A, Montiel-Cervantes L, García-Ruiz Esparza M,1 Vela-Ojeda J; Mexican Hematology Study Group. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis. Ann Hematol 2007;86(12):871-877.
Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, et al. Systematic review: efficacy and safety of rituximab for adults with Idiopathic thrombocytopenic purpura. Ann Intern Med 2007;2;146(1):25-33.
Burzynski J. New options after first-line therapy for chronic immune thrombocytopenic purpura. Am J Health Syst Pharm 2009;15;66(2 Suppl 2):S11-21.